<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066648</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001X2105</org_study_id>
    <nct_id>NCT03066648</nct_id>
  </id_info>
  <brief_title>Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS</brief_title>
  <official_title>Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination&#xD;
      with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine or azacitidine in AML&#xD;
      and intermediate or high- risk MDS patients, and to identify recommended doses for future&#xD;
      studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is comprised of six combination arms:&#xD;
Evaluation of a fixed dose of the standard of care agent decitabine, in combination with fixed dose PDR001 (Arm 1)&#xD;
Evaluation of a fixed dose of the standard of care agent decitabine in combination with escalating dose MBG453 (Arm 2)&#xD;
Evaluation of a fixed dose of the standard of care agent decitabine in combination with fixed dose of PDR001 and escalating dose of MBG453 (Arm 3) *&#xD;
Evaluation of an escalating dose of MBG453 (Arm 4)&#xD;
Evaluation of a fixed dose of PDR001 in combination with an escalating dose of MBG453 (Arm 5)&#xD;
Evaluation of a fixed dose of the standard of care agent azacitidine in combination with an escalating dose of MBG453 (Arm 6)&#xD;
The evaluation of decitabine with the combination of PDR001 and MBG453 (Arm 3) will start after Novartis and Investigator's review of the available safety and tolerability data from each of the first two cohorts in Arm 1 and Arm 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of MBG453 single agent treatment or MBG453 in combination with PDR001 or PDR001 and/or MBG453 in combination with decitabine or azacitidine.</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of AEs and SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>2 months</time_frame>
    <description>The incidence of DLTs during the first two cycles of treatment with MBG453 in combination with PDR001 or PDR001 and/or MBG453 in combination with decitabine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>1 month</time_frame>
    <description>The incidence of DLTs during the first cycle of MBG453 single agent treatment or during the first two cycles of treatment with MBG453 in combination with PDR001 or PDR001 and/or MBG453 in combination with decitabine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of MBG453 single agent treatment or MBG453 in combination with PDR001 or PDR001 and/or MBG453 in combination with decitabine or azacitidine.</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of AEs and SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of PDR001, MBG453, decitabine and azacitidine.</measure>
    <time_frame>24 months</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of PDR001, MBG453, decitabine and azacitidine</measure>
    <time_frame>24 months</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of PDR001, MBG453, decitabine and azacitidine</measure>
    <time_frame>24 months</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of PDR001, MBG453, decitabine and azacitidine</measure>
    <time_frame>24 months</time_frame>
    <description>Half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine ORR in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine BOR in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine PFS in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine TTP in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine DOR in each arm of the study</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Leukemia</condition>
  <condition>Leukemia, Myeloid</condition>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Preleukemia</condition>
  <condition>Bone Marrow Diseases</condition>
  <condition>Hematologic Diseases</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Decitabine and PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine in combination with PDR001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine and MBG453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine in combination with MBG453</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine, PDR001 and MBG453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine in combination with PDR001 and MBG453</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBG453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBG453 alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBG453 and PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBG453 in combination with PDR001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azacitidine and MBG453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine in combination with MBG453</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.</description>
    <arm_group_label>Decitabine and MBG453</arm_group_label>
    <arm_group_label>Decitabine and PDR001</arm_group_label>
    <arm_group_label>Decitabine, PDR001 and MBG453</arm_group_label>
    <other_name>5-aza-2'-deoxycytidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.</description>
    <arm_group_label>Decitabine and PDR001</arm_group_label>
    <arm_group_label>Decitabine, PDR001 and MBG453</arm_group_label>
    <arm_group_label>MBG453 and PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBG453</intervention_name>
    <description>MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).</description>
    <arm_group_label>Azacitidine and MBG453</arm_group_label>
    <arm_group_label>Decitabine and MBG453</arm_group_label>
    <arm_group_label>Decitabine, PDR001 and MBG453</arm_group_label>
    <arm_group_label>MBG453</arm_group_label>
    <arm_group_label>MBG453 and PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation</description>
    <arm_group_label>Azacitidine and MBG453</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent must be obtained prior to any screening procedures&#xD;
&#xD;
          2. Male or female patients ≥ 18 years of age who present with one of the following:&#xD;
&#xD;
             Arms 1-3:&#xD;
&#xD;
               -  Refractory/relapsed AML following ≥1 prior therapies and are deemed by the&#xD;
                  investigator not to be candidates for standard therapy, including re-induction&#xD;
                  with cytarabine or other established chemotherapy regimens for patients with AML&#xD;
                  (patients who are suitable for standard re-induction chemotherapy or&#xD;
                  hematopoietic stem cell transplantation and willing to receive it are excluded)&#xD;
&#xD;
               -  Newly diagnosed AML patients who are suitable for treatment with decitabine&#xD;
                  (patients who are suitable for standard induction chemotherapy or hematopoietic&#xD;
                  stem cell transplantation and willing to receive it are excluded)&#xD;
&#xD;
               -  Intermediate or high risk MDS or MDS/MPN including CMML (patients who are&#xD;
                  suitable for standard re-induction chemotherapy or hematopoietic stem cell&#xD;
                  transplantation and willing to receive it are excluded)&#xD;
&#xD;
             Arms 4-5:&#xD;
&#xD;
               -  Refractory / relapsed AML following ≥1 prior therapies (Arms 4a &amp; 5a)&#xD;
&#xD;
               -  Intermediate or high risk MDS or MDS/MPN including CMML who have failed&#xD;
                  hypomethylating agent therapy (Arms 4b &amp; 5b) (Note: hypomethylating agent failure&#xD;
                  is defined as progressive disease on hypomethylating agent therapy or lack of&#xD;
                  clinically meaningful response as deemed by investigator after at least 4 cycles&#xD;
                  of hypomethylating agent therapy.)&#xD;
&#xD;
             Arm 6:&#xD;
&#xD;
               -  Newly diagnosed AML patients who are suitable for treatment with azacitidine&#xD;
                  (patients who are suitable for standard induction chemotherapy or hematopoietic&#xD;
                  stem cell transplantation and willing to receive it are excluded) (Arm 6a)&#xD;
&#xD;
               -  Intermediate or high-risk MDS or MDS/MPN including CMML (patients who are&#xD;
                  suitable for standard induction chemotherapy or hematopoietic stem cell&#xD;
                  transplantation and willing to receive it are excluded) (Arm 6b)&#xD;
&#xD;
          3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
          4. Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to&#xD;
             the institutions guidelines and be willing to undergo a bone marrow aspirate&#xD;
             and/biopsy at screening, during and at the end of therapy on this study. Exceptions&#xD;
             may be considered after documented discussion with Novartis.&#xD;
&#xD;
          5. Arms 1-3: Patients must be fit for standard treatment with decitabine as determined by&#xD;
             the investigator and as per local decitabine package insert.&#xD;
&#xD;
          6. Arm 6: Patients must be fit for standard treatment with azacitidine as determined by&#xD;
             the investigator and as per the local azacitidine package insert.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Arms 1-3 or Arm 6: Patients who have received prior hypomethylating agent treatment&#xD;
             for AML or MDS.&#xD;
&#xD;
          2. Patients with active, known or suspected autoimmune disease. Patients with vitiligo,&#xD;
             type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis&#xD;
             not requiring systemic treatment or conditions not expected to recur should not be&#xD;
             excluded.&#xD;
&#xD;
          3. History of, or current drug-induced interstitial lung disease or pneumonitis grade ≥&#xD;
             2.&#xD;
&#xD;
          4. Patients who discontinued prior PD-1 or PD-L1 directed therapy due to a treatment&#xD;
             related toxicity should not be included in the PDR001 containing arms of the study.&#xD;
             Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated&#xD;
             for skin rash or with replacement therapy for endocrinopathies should not be excluded.&#xD;
&#xD;
          5. Systemic antineoplastic therapy (including cytotoxic chemotherapy, alphainterferon,&#xD;
             kinase inhibitors or other targeted small molecules, and toxinimmunoconjugates) or any&#xD;
             experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the&#xD;
             first dose of study treatment.&#xD;
&#xD;
          6. Systemic chronic corticosteroid therapy (&gt;10 mg/day prednisone or equivalent) or any&#xD;
             immunosuppressive therapy within 7 days of first dose of study treatment. Topical,&#xD;
             inhaled, nasal and ophthalmic steroids are allowed.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN 00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF4 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 18, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Myelodysplastic syndromes</keyword>
  <keyword>Chronic Myelomonocytic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

